Top Markets
Coin of the day
Applied Molecular Transport Inc. Applied Molecular Transport Inc.

Applied Molecular Transport Inc.

AMTI
株式のランク #32732
Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the... Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.
株価
$0.263
最終同期: 2023-12-29
時価総額
$9.26M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Applied Molecular Transport Inc. (AMTI)

カテゴリー

Applied Molecular Transport Inc.(AMTI)の利益
2026 時点の利益 TTM: 0
Applied Molecular Transport Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Applied Molecular Transport Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益